Shorts

1:30
Bridging the Gap Between Patients and Clinical Trials
a year ago
by
Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS

0:56
Reviewing Ruxolitinib's Expanded Indication for Pediatric Patients With AD
a year ago
by
Nicole Harter, MD

0:42
Addressing Health Care Bias in Treating Patients of Color
a year ago
by
Buchi Neita, MCMSc, PA-C

0:55
How Deuruxolitinib Blocks Autoimmune Hair Loss in Alopecia Areata
a year ago
by
Vimal Prajapati, MD, FRCPC, DABD

1:30
Essential Recommendations for Dermatologists
a year ago
by
Nayan Patel, PharmD

1:30
Skin Care Trends: Facts vs Misinformation
a year ago
by
Anthony M. Rossi, MD, FAAD, FACMS
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
3
Alopecia Areata Awareness Month: 2026 in Review
4
From Mechanism to Management: Navigating Male Pattern Hair Loss and New Topical Therapies
5

